Last reviewed · How we verify
ASN008
ASN008 is a small molecule that targets the SGLT1 transporter.
ASN008 is a small molecule that targets the SGLT1 transporter. Used for Type 2 diabetes.
At a glance
| Generic name | ASN008 |
|---|---|
| Sponsor | Formation Bio, Inc. |
| Drug class | SGLT1 inhibitor |
| Target | SGLT1 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT1, ASN008 aims to reduce glucose absorption in the gut, thereby lowering blood glucose levels. This mechanism is thought to be beneficial for the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis (PHASE2)
- Study to Evaluate ASN008 Topical Gel (TG) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASN008 CI brief — competitive landscape report
- ASN008 updates RSS · CI watch RSS
- Formation Bio, Inc. portfolio CI